New insider activity at Corcept Therapeutics ( (CORT) ) has taken place on June 18, 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gary Charles Robb, the Chief Business Officer of Corcept Therapeutics, recently executed a sale of 3,185 shares of the company’s stock, amounting to a total transaction value of $225,402.
Spark’s Take on CORT Stock
According to Spark, TipRanks’ AI Analyst, CORT is a Outperform.
Corcept Therapeutics’ strong financial performance and positive earnings outlook drive the stock’s overall score. However, technical indicators and high valuation present cautionary signals. Despite challenges like net income decline and ongoing litigation, the company’s growth potential remains significant.
To see Spark’s full report on CORT stock, click here.
More about Corcept Therapeutics
YTD Price Performance: 43.79%
Average Trading Volume: 1,686,352
Technical Sentiment Signal: Buy
Current Market Cap: $7.52B